

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8097153

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PARKINSON'S INSTITUTE	03/29/2023
RECEIVING PARTY DATA	
Name:	TYLER MEDICAL RESEARCH, LLC
Street Address:	110 N COLLEGE #1002
City:	TYLER
State/Country:	TEXAS
Postal Code:	75702
PROPERTY NUMBERS Total: 6	
Property Type	Number
Patent Number:	9187567
Patent Number:	9417239
Patent Number:	9464273
Patent Number:	10233422
Patent Number:	10631772
Patent Number:	10653686
CORRESPONDENCE DATA	
Fax Number:	(919)882-8195
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9193482194
Email:	docket@nkpatentlaw.com
Correspondent Name:	NK PATENT LAW
Address Line 1:	4101 LAKE BOONE TRAIL
Address Line 2:	SUITE 218
Address Line 4:	RALEIGH, NORTH CAROLINA 27607
ATTORNEY DOCKET NUMBER:	1470/2 ASSIGN
NAME OF SUBMITTER:	SANDRA HESS
SIGNATURE:	/Sandra Hess/
DATE SIGNED:	08/04/2023

Total Attachments: 13

source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page1.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page2.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page3.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page4.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page5.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page6.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page7.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page8.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page9.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page10.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page11.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page12.tif
source=1470-2ASSIGN-20230329-Assign-Parkinson'sInstitute-to-TylerMedicalResearch-signed#page13.tif

PATENT ASSIGNMENT

WHEREAS, Parkinson's Institute (hereinafter "ASSIGNOR"), a corporation of the state of California having a place of business at 2500 Hospital Drive, Building 10, 6 Suite 1, Mountain View, CA 94040 has acquired the entire right, title and interest in the patent applications and patents listed on the attached Schedule A; and

WHEREAS, Tyler Medical Research, LLC, (hereinafter "ASSIGNEE"), a Texas Limited Liability Company with place of business in the state of Texas having a place of residence at 110 N College #1002, Tyler, TX 75702 desires to acquire the patent applications and patents listed on the attached Schedule A and Schedule B.

NOW, THEREFORE, in consideration of good and valuable consideration paid by ASSIGNEE, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby:

1. Agrees to sell, assign, transfer and convey and hereby does sell, assign, transfer and convey unto ASSIGNEE, the entire interest in and to said patent applications and patents listed on the attached Schedule A, in and to the inventions therein set forth and any reissue, reexamination, renewal, divisional, or continuation thereof.

2. Agrees to sell, assign, transfer and convey and hereby does sell, assign, transfer and convey unto ASSIGNEE, all claims for damages or other remedies by reason of past infringement of the patents and the right to sue for and collect such damages for its own use, the same to be held and enjoyed by ASSIGNEE for its own use and enjoyment

and the use and enjoyment of its successors, assigns or other legal representatives to the full ends of the terms for which the patents are granted or reissued as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this assignment and sale had not been made.

3. Agrees to sell, assign, transfer and convey and hereby does sell, assign, transfer and convey unto ASSIGNEE the full, exclusive, and entire right, title and interest in and to any non-U.S. applications corresponding to the U.S. patent applications and patents listed on the attached Schedule A, in whole or in part, in and to any patents and similar protective rights granted on said non-U.S. applications, and in and to the right to claim any applicable priority rights arising from or required for said non-U.S. applications under the terms of any applicable conventions, treaties, statutes, or regulations; said non-U.S. applications to be filed and issued in the name of the ASSIGNEE or its designee insofar as permitted by applicable law.

IN WITNESS WHEREOF, I have executed this Patent Assignment this 29th day of March, 2023.

Parlerson's Institute [Assignor]

By: Brent R. Parlerson
Title: CEO

Schedule A

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
US9187567B2	US	B2	Assay to determine LRRK2 activity in parkinson's disease	ACTIVE	US9187567B2.PDF	US9187567B2.PAR
US9417239B2	US	B2	Assay to determine LRRK2 activity in parkinson's disease	ACTIVE	US9417239B2.PDF	US9417239B2.PAR
WO/2012/159079A1	WO	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	WO/2012/159079A1.PDF	WO/2012/159079A1.PAR
US20140141451A1	US	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	US20140141451A1.PDF	US20140141451A1.PAR
US20160312194A1	US	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	US20160312194A1.PDF	US20160312194A1.PAR
US20160011196A1	US	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	US20160011196A1.PDF	US20160011196A1.PAR
EP2710041A1	EP	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	EP2710041A1.PDF	EP2710041A1.PAR
EP2710041A4	EP	A4	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	UNKNOWN	EP2710041A4.PDF	EP2710041A4.PAR
GB2448224A	GB	A	Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like	INACTIVE	GB2448224A.PDF	GB2448224A.PAR
GB2468424A	GB	A	Composition for the reduction of side-effects of dopaminergic agents	INACTIVE	GB2468424A.PDF	GB2468424A.PAR
US20150037257A1	US	A1	COMPOSITIONS AND METHODS FOR HIGH-THROUGHPUT SCREENING IN SKIN FIBROBLASTS WITH AN ALPHA-SYNUCLEIN TRIPLICATION	INACTIVE	US20150037257A1.PDF	US20150037257A1.PAR
EP2361089A1	EP	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION	INACTIVE	EP2361089A1.PDF	EP2361089A1.PAR
CN102245180A	CN	A	Compositions and methods for the treatment of altered alpha-synuclein function	INACTIVE	CN102245180A.PDF	CN102245180A.PAR
US20120052053A1	US	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION	INACTIVE	US20120052053A1.PDF	US20120052053A1.PAR
AU2014265137A1	AU	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION	INACTIVE	AU2014265137A1.PDF	AU2014265137A1.PAR
AU2009314447A1	AU	A1	Compositions and methods for the treatment of altered alpha-synuclein function	INACTIVE	AU2009314447A1.PDF	AU2009314447A1.PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
US9187567B2	US	B2	Assay to determine LRRK2 activity in parkinson's disease	ACTIVE	US9187567B2-PDF	US9187567B2-PAR
US9417239B2	US	B2	Assay to determine LRRK2 activity in parkinson's disease	ACTIVE	US9417239B2-PDF	US9417239B2-PAR
WO/2012/159079A1	WO	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	WO/2012/159079A1-PDF	WO/2012/159079A1-PAR
US20140141451A1	US	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	US20140141451A1-PDF	US20140141451A1-PAR
US20160312194A1	US	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	US20160312194A1-PDF	US20160312194A1-PAR
US20160011196A1	US	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	US20160011196A1-PDF	US20160011196A1-PAR
EP2710041A1	EP	A1	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	INACTIVE	EP2710041A1-PDF	EP2710041A1-PAR
EP2710041A4	EP	A4	ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE	UNKNOWN	EP2710041A4-PDF	EP2710041A4-PAR
GB2448224A	GB	A	Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like	INACTIVE	GB2448224A-PDF	GB2448224A-PAR
GB2468424A	GB	A	Composition for the reduction of side-effects of dopaminergic agents	INACTIVE	GB2468424A-PDF	GB2468424A-PAR
US20150037257A1	US	A1	COMPOSITIONS AND METHODS FOR HIGH-THROUGHPUT SCREENING IN SKIN FIBROBLASTS WITH AN ALPHA-SYNUCLEIN TRIPLICATION	INACTIVE	US20150037257A1-PDF	US20150037257A1-PAR
EP2361089A1	EP	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION	INACTIVE	EP2361089A1-PDF	EP2361089A1-PAR
CN102245180A	CN	A	Compositions and methods for the treatment of altered alpha-synuclein function	INACTIVE	CN102245180A-PDF	CN102245180A-PAR
US20120052053A1	US	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION	INACTIVE	US20120052053A1-PDF	US20120052053A1-PAR
AU2014265137A1	AU	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION	INACTIVE	AU2014265137A1-PDF	AU2014265137A1-PAR
AU2009314447A1	AU	A1	Compositions and methods for the treatment of altered alpha-synuclein function	INACTIVE	AU2009314447A1-PDF	AU2009314447A1-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
US20150044193A1	US	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α -SYNUCLEIN FUNCTION	INACTIVE	US20150044193A1-PDF	US20150044193A1-PAR
CA2745451A1	CA	A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α -SYNUCLEIN FUNCTION	INACTIVE	CA2745451A1-PDF	CA2745451A1-PAR
GB2480159A	GB	A	Compositions and methods for the treatment of altered α -synuclein function	INACTIVE	GB2480159A-PDF	GB2480159A-PAR
EP2361089A4	EP	A4	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION	UNKNOWN	EP2361089A4-PDF	EP2361089A4-PAR
WO/2010/056413A2	WO	A2	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α -SYNUCLEIN FUNCTION	INACTIVE	WO/2010/056413A2-PDF	WO/2010/056413A2-PAR
JP2015127343A	JP	A	COMPOSITIONS AND METHODS FOR TREATMENT OF ALTERED α -SYNUCLEIN FUNCTION	INACTIVE	JP2015127343A-PDF	JP2015127343A-PAR
US10653686B2	US	B2	Compositions and methods for treatment of symptoms in parkinson's disease patients	ACTIVE	US10653686B2-PDF	US10653686B2-PAR
US20130017259A1	US	A1	Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients	INACTIVE	US20130017259A1-PDF	US20130017259A1-PAR
US20160220553A1	US	A1	COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS	INACTIVE	US20160220553A1-PDF	US20160220553A1-PAR
US20190054078A1	US	A1	COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS	INACTIVE	US20190054078A1-PDF	US20190054078A1-PAR
WO/2013/006643A1	WO	A1	COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS	INACTIVE	WO/2013/006643A1-PDF	WO/2013/006643A1-PAR
US20200306240A1	US	A1	COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS	INACTIVE	US20200306240A1-PDF	US20200306240A1-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
EP2729148A1	EP	A1	COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS	INACTIVE	EP2729148A1.PDF	EP2729148A1-PAR
CA2841785A1	CA	A1	COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS	INACTIVE	CA2841785A1.PDF	CA2841785A1-PAR
EP2729148A4	EP	A4	COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS	UNKNOWN	EP2729148A4.PDF	EP2729148A4-PAR
IL201269A	IL	A	Compositions comprising nicotine for reduction of side effects of dopaminergic agents	ACTIVE	IL201269A.PDF	IL201269A-PAR
GB2463833B	GB	B	Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders	INACTIVE	GB2463833B.PDF	GB2463833B-PAR
US20210047623A1	US	A1	CRISPR KNOCK-OUT OF THE ALPHA-SYNUCLEIN TRIPLICATION MODEL OF PARKINSON'S DISEASE	INACTIVE	US20210047623A1.PDF	US20210047623A1-PAR
WO/2019/152432A1	WO	A1	CRISPR KNOCK-OUT OF THE ALPHA-SYNUCLEIN TRIPLICATION MODEL OF PARKINSON'S DISEASE	INACTIVE	WO/2019/152432A1.PDF	WO/2019/152432A1-PAR
WO/2019/152433A1	WO	A1	CRISPR-BASED DOWNREGULATION OF ALPHA-SYNUCLEIN EXPRESSION AS A NOVEL PARKINSON'S DISEASE THERAPEUTIC	INACTIVE	WO/2019/152433A1.PDF	WO/2019/152433A1-PAR
US20210047627A1	US	A1	CRISPR-BASED DOWNREGULATION OF ALPHA-SYNUCLEIN EXPRESSION AS A NOVEL PARKINSON'S DISEASE THERAPEUTIC	INACTIVE	US20210047627A1.PDF	US20210047627A1-PAR
US10631772B2	US	B2	Diagnosis of neurodegenerative disorders	ACTIVE	US10631772B2.PDF	US10631772B2-PAR
WO/2009/152521A2	WO	A2	DIAGNOSIS OF NEURODEGENERATIVE DISORDERS	INACTIVE	WO/2009/152521A2.PDF	WO/2009/152521A2-PAR
US9622669B2	US	B2	Diagnosis of neurodegenerative disorders	INACTIVE	US9622669B2.PDF	US9622669B2-PAR
US20170238861A1	US	A1	DIAGNOSIS OF NEURODEGENERATIVE DISORDERS	INACTIVE	US20170238861A1.PDF	US20170238861A1-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
WO/2009/152521A3	WO	A3	DIAGNOSIS OF NEURODEGENERATIVE DISORDERS	UNKNOWN	WO/2009/152521A3-PDF	WO/2009/152521A3-PAR
US20110160603A1	US	A1	DIAGNOSIS OF NEUROGENERATIVE DISORDERS	INACTIVE	US20110160603A1-PDF	US20110160603A1-PAR
EP2721145A1	EP	A1	HIGH THROUGH-PUT SCREENING IN SKIN FIBROBLASTS WITH AN ALPHA-SYNUCLEIN TRIPLICATION	INACTIVE	EP2721145A1-PDF	EP2721145A1-PAR
WO/2012/174477A1	WO	A1	HIGH THROUGH-PUT SCREENING IN SKIN FIBROBLASTS WITH AN ALPHA-SYNUCLEIN TRIPLICATION	INACTIVE	WO/2012/174477A1-PDF	WO/2012/174477A1-PAR
EP2721145A4	EP	A4	HIGH THROUGH-PUT SCREENING IN SKIN FIBROBLASTS WITH AN ALPHA-SYNUCLEIN TRIPLICATION	UNKNOWN	EP2721145A4-PDF	EP2721145A4-PAR
WO/2012/174477A8	WO	A8	HIGH THROUGH-PUT SCREENING IN SKIN FIBROBLASTS WITH AN ALPHA-SYNUCLEIN TRIPLICATION	UNKNOWN	WO/2012/174477A8-PDF	WO/2012/174477A8-PAR
US20200165358A1	US	A1	METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF SYNUCLEINOPATHIES	INACTIVE	US20200165358A1-PDF	US20200165358A1-PAR
ES2521494T3	ES	T3	Methods and compositions for reducing the side effects of therapeutic treatments	UNKNOWN	ES2521494T3-PDF	ES2521494T3-PAR
IN2009DN06255A	IN	A	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	ACTIVE	IN2009DN06255A-PDF	IN2009DN06255A-PAR
HK1147951B	HK	B	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	ACTIVE	HK1147951B-PDF	HK1147951B-PAR
US20080260825A1	US	A1	Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments	INACTIVE	US20080260825A1-PDF	US20080260825A1-PAR
US7718677B2	US	B2	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	US7718677B2-PDF	US7718677B2-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
US20100196463A1	US	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	US20100196463A1.PDF	US20100196463A1-PAR
US20110077276A1	US	A1	Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments	INACTIVE	US20110077276A1.PDF	US20110077276A1-PAR
US20100029723A1	US	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	US20100029723A1.PDF	US20100029723A1-PAR
EP1977746A1	EP	A1	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	EP1977746A1.PDF	EP1977746A1-PAR
US20100158895A1	US	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	US20100158895A1.PDF	US20100158895A1-PAR
US20100166735A1	US	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	US20100166735A1.PDF	US20100166735A1-PAR
EP1977746B1	EP	B1	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	EP1977746B1.PDF	EP1977746B1-PAR
US20100159004A1	US	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	US20100159004A1.PDF	US20100159004A1-PAR
US20160235732A1	US	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	US20160235732A1.PDF	US20160235732A1-PAR
WO/2008/122049A2	WO	A2	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	WO/2008/122049A2.PDF	WO/2008/122049A2-PAR
US20180110768A1	US	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	US20180110768A1.PDF	US20180110768A1-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
EP2322166A1	EP	A1	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	EP2322166A1-PDF	EP2322166A1-PAR
EP2322168A1	EP	A1	Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments	INACTIVE	EP2322168A1-PDF	EP2322168A1-PAR
EP2322167A1	EP	A1	Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments	INACTIVE	EP2322167A1-PDF	EP2322167A1-PAR
CN101772346A	CN	A	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	CN101772346A-PDF	CN101772346A-PAR
JP2016020385A	JP	A	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	JP2016020385A-PDF	JP2016020385A-PAR
KR101122469B1	KR	B1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	KR101122469B1-PDF	KR101122469B1-PAR
KR20110075044A	KR	A	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	KR20110075044A-PDF	KR20110075044A-PAR
JP2013155209A	JP	A	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	JP2013155209A-PDF	JP2013155209A-PAR
HK1147951A1	HK	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	HK1147951A1-PDF	HK1147951A1-PAR
CA2682323A1	CA	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	CA2682323A1-PDF	CA2682323A1-PAR
CN101772346B	CN	B	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	CN101772346B-PDF	CN101772346B-PAR
HK1145978A1	HK	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	HK1145978A1-PDF	HK1145978A1-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
KR20100045406A	KR	A	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	KR20100045406A-PDF	KR20100045406A-PAR
HK1135037A1	HK	A1	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	HK1135037A1-PDF	HK1135037A1-PAR
GB2461412B	GB	B	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	GB2461412B-PDF	GB2461412B-PAR
AU2008232453B8	AU	B8	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	AU2008232453B8-PDF	AU2008232453B8-PAR
CN103977003A	CN	A	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	CN103977003A-PDF	CN103977003A-PAR
GB2468424B	GB	B	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	GB2468424B-PDF	GB2468424B-PAR
AU2011203482A1	AU	A1	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	AU2011203482A1-PDF	AU2011203482A1-PAR
AU2011203482B2	AU	B2	Methods and compositions for reduction of side effects of therapeutic treatments	INACTIVE	AU2011203482B2-PDF	AU2011203482B2-PAR
IN6255DEN2009A	IN	A	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	INACTIVE	IN6255DEN2009A-PDF	IN6255DEN2009A-PAR
EP1977746B8	EP	B8	Methods and compositions for reduction of side effects of therapeutic treatments	UNKNOWN	EP1977746B8-PDF	EP1977746B8-PAR
WO/2008/122049A3	WO	A3	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS	UNKNOWN	WO/2008/122049A3-PDF	WO/2008/122049A3-PAR
AU2008232453A8	AU	A8	Methods and compositions for reduction of side effects of therapeutic treatments	UNKNOWN	AU2008232453A8-PDF	AU2008232453A8-PAR
WO/2009/003147A1	WO	A1	METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS	INACTIVE	WO/2009/003147A1-PDF	WO/2009/003147A1-PAR
GB2463833A	GB	A	Methods and compositions for the treatment of neurological disorders	INACTIVE	GB2463833A-PDF	GB2463833A-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
US20070214509A1	US	A1	Methods and systems for identifying compounds that modulate alpha-synuclein aggregation	INACTIVE	US20070214509A1.PDF	US20070214509A1-PAR
US20090010894A1	US	A1	METHODS AND SYSTEMS FOR IDENTIFYING COMPOUNDS THAT MODULATE ALPHA-SYNUCLEIN AGGREGATION	INACTIVE	US20090010894A1.PDF	US20090010894A1-PAR
US20190358349A1	US	A1	METHODS FOR EVALUATION OF TREATMENT AND PROGRESSION OF NEUROLOGICAL DISORDERS	INACTIVE	US20190358349A1.PDF	US20190358349A1-PAR
US20180179594A1	US	A1	MULTIPLE SYSTEM ATROPHY AND THE TREATMENT THEREOF	INACTIVE	US20180179594A1.PDF	US20180179594A1-PAR
WO/2010/008486A2	WO	A2	PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF	INACTIVE	WO/2010/008486A2.PDF	WO/2010/008486A2-PAR
WO/2010/008486A3	WO	A3	PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF	UNKNOWN	WO/2010/008486A3.PDF	WO/2010/008486A3-PAR
US20190085394A1	US	A1	REFINING DIAGNOSIS AND TREATMENT OF COMPLEX MULTI-SYMP TOM NEUROLOGICAL DISORDERS	INACTIVE	US20190085394A1.PDF	US20190085394A1-PAR
WO/2017/106363A1	WO	A1	REFINING DIAGNOSIS AND TREATMENT OF COMPLEX MULTI-SYMP TOM NEUROLOGICAL DISORDERS	INACTIVE	WO/2017/106363A1.PDF	WO/2017/106363A1-PAR
WO/2014/085830A2	WO	A2	SCREENING ASSAYS FOR THERAPEUTICS FOR PARKINSON'S DISEASE	INACTIVE	WO/2014/085830A2.PDF	WO/2014/085830A2-PAR
US20160010154A1	US	A1	SCREENING ASSAYS FOR THERAPEUTICS FOR PARKINSON'S DISEASE	INACTIVE	US20160010154A1.PDF	US20160010154A1-PAR
WO/2014/085830A3	WO	A3	SCREENING ASSAYS FOR THERAPEUTICS FOR PARKINSON'S DISEASE	UNKNOWN	WO/2014/085830A3.PDF	WO/2014/085830A3-PAR
GB2448224B	GB	B	Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent	INACTIVE	GB2448224B.PDF	GB2448224B-PAR
GB2461412A	GB	A	Use of a nicotinic receptor agonist in the treatment of dyskinesias associated with dopaminergic agent therapy	INACTIVE	GB2461412A.PDF	GB2461412A-PAR
US20120214241A1	US	A1	ZINC FINGER NUCLEASE MODIFICATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) MUTANT FIBROBLASTS AND IPSCS	INACTIVE	US20120214241A1.PDF	US20120214241A1-PAR

Document #	Country Code	Kind	Title	Document Status	PDF	3rd Party Patent Analysis Report
WO/2012/087756A1	WO	A1	ZINC FINGER NUCLEASE MODIFICATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) MUTANT FIBROBLASTS AND IPSCS	INACTIVE	WO/2012/087756A1-PDF	WO/2012/087756A1-PAR

Schedule B

Patent PDF & Patent Reports	Patent Title
<u>US9187567B2-PAR</u>	Assay to determine LRRK2 Activity in Parkinson's Disease
<u>US9417239B2-PAR</u>	Assay to Determine LRRK2 Activity in Parkinson's Disease
<u>US1065368B2-PAR</u>	Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
<u>US10631772B2-PAR</u>	Diagnosis of Neurodegenerative Disorders
<u>US10233422B2-PAR</u>	Pluripotent Cell Lines and Methods of Use Thereof
<u>US9464273B2-PAR</u>	Pluripotent Cell Lines and Methods of Use Thereof